|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
594,697 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$56,737,885 |
Total People Sold |
5 |
5 |
6 |
7 |
Total Sell Transactions |
11 |
15 |
24 |
53 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lewis Alan |
Director |
|
2014-12-04 |
4 |
S |
$89.90 |
$674,225 |
D/D |
(7,500) |
21,400 |
|
- |
|
Lewis Alan |
Director |
|
2014-12-04 |
4 |
OE |
$21.51 |
$161,325 |
D/D |
7,500 |
28,900 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-12-03 |
4 |
S |
$91.01 |
$1,092,161 |
D/D |
(12,000) |
31,590 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-12-03 |
4 |
OE |
$38.59 |
$463,080 |
D/D |
12,000 |
43,590 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-12-02 |
4 |
S |
$91.82 |
$459,100 |
D/D |
(5,000) |
4,593 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-12-02 |
4 |
OE |
$28.23 |
$141,150 |
D/D |
5,000 |
9,593 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-12-01 |
4 |
S |
$90.25 |
$627,238 |
D/D |
(6,950) |
4,593 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-12-01 |
4 |
OE |
$14.39 |
$145,785 |
D/D |
6,950 |
11,543 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-11-26 |
4 |
S |
$88.97 |
$302,508 |
D/D |
(3,400) |
4,593 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-11-25 |
4 |
AS |
$89.75 |
$1,795,000 |
D/D |
(20,000) |
64,426 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-11-25 |
4 |
OE |
$26.49 |
$529,800 |
D/D |
20,000 |
84,426 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-25 |
4 |
AS |
$90.00 |
$180,000 |
I/I |
(2,000) |
43,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-25 |
4 |
OE |
$12.99 |
$25,980 |
I/I |
2,000 |
45,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-13 |
5 |
GD |
$0.00 |
$0 |
D/D |
2,400 |
230,768 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-12 |
4 |
S |
$81.51 |
$81,513 |
D/D |
(1,000) |
228,157 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-11-10 |
4 |
S |
$86.55 |
$1,730,982 |
D/D |
(20,000) |
76,550 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-11-10 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
96,550 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-10 |
4 |
S |
$87.00 |
$348,000 |
I/I |
(4,000) |
43,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-10 |
4 |
OE |
$12.99 |
$51,960 |
I/I |
4,000 |
47,195 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2014-11-05 |
5 |
GA |
$0.00 |
$0 |
I/I |
46 |
23,935 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2014-11-05 |
5 |
GD |
$0.00 |
$0 |
D/D |
46 |
99,200 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-11-03 |
4 |
S |
$85.33 |
$256,002 |
I/I |
(3,000) |
43,195 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-11-03 |
4 |
AS |
$83.54 |
$3,926 |
D/D |
(47) |
31,590 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-10-31 |
4 |
A |
$31.26 |
$1,469 |
D/D |
47 |
31,637 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-10-30 |
4 |
S |
$83.20 |
$1,247,930 |
D/D |
(15,000) |
64,426 |
|
- |
|
1335 Records found
|
|
Page 2 of 54 |
|
|